Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $8.00 at Oppenheimer

Key Points

• Oppenheimer has raised its price target for Aquestive Therapeutics from $7.00 to $8.00, suggesting a potential upside of 47.60% from the stock's previous close.
• Multiple analysts have varying ratings on the stock, with the consensus being an average rating of "Buy" and a target price of $10.29.
• Aquestive Therapeutics reported earnings of ($0.14) per share, exceeding estimates, with revenue of $10.00 million which was below the expected $11.32 million.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) had its price objective raised by research analysts at Oppenheimer from $7.00 to $8.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Oppenheimer's target price points to a potential upside of 47.60% from the company's previous close.

Other equities analysts also recently issued research reports about the stock. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Lifesci Capital raised shares of Aquestive Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 3rd. Finally, Zacks Research raised Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Aquestive Therapeutics currently has an average rating of "Buy" and a consensus target price of $10.29.

Aquestive Therapeutics Trading Up 7.1%

NASDAQ AQST opened at $5.42 on Monday. The stock has a market capitalization of $540.48 million, a price-to-earnings ratio of -7.74 and a beta of 1.82. The stock has a 50-day moving average of $3.98 and a 200 day moving average of $3.25. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Summit Wealth & Retirement Planning Inc. purchased a new stake in Aquestive Therapeutics during the 1st quarter worth $29,000. Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics during the first quarter valued at about $31,000. BNP Paribas Financial Markets increased its position in shares of Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock worth $31,000 after acquiring an additional 4,134 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Aquestive Therapeutics in the first quarter worth about $33,000. Finally, USAdvisors Wealth Management LLC acquired a new position in shares of Aquestive Therapeutics in the second quarter worth about $33,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.